December 02, 2013
1 min read
Save

NxStage Medical introduces new products at Kidney Week

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NxStage Medical Inc. introduced three new products at the American Society of Nephrology Kidney Week 2013 meeting in Atlanta last month. The new offerings include the NxStage System One S model, Nx2me Connected Health, and the NxStage dosing calculator.

The NxStage System One S's higher dialysate flow rates allow for a wider range of flexible therapy options and can provide a higher dose in the same time as it would take with the System One, the company said.

(NxStage Kidney Care opens its first dialysis center)

Nx2me Connected Health leverages tablets, cloud computing, and wireless communications. A key component of this solution is the Nx2me app, developed for the iPad and used by patients at home. The app collects NxStage System One cycler data, as well as patient information such as blood pressure and weight. Patients can review, confirm, and transmit this data to their centers after each treatment. Dialysis center staff can access the transmitted data using the Nx2me Clinician Portal, gaining enhanced capabilities to review and follow treatment adherence and progress.

The new NxStage dosing calculator is an online tool that helps physicians develop prescriptions tailored to patients' clinical and lifestyle objectives. Using formulas from peer-reviewed publications, the dosing calculator quickly displays a wide range of therapy options to assist physicians in prescribing for a desired dose. The calculator is a free service and can be accessed directly at http://dosingcalculator.nxstage.com.

(Swiss company joins AWAK in development of smaller home hemodialysis machine)

"I'm very proud of our continued commitment to innovation and our ability to bring new products to market," said Jeffrey H. Burbank, CEO of NxStage. "We are really excited about the potential of these enhancements to improve both ease of use of our therapy and efficiency for providers, clinicians, and most importantly, our patients."